Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Elanco Animal Health (ELAN)

NYSE: ELAN · Veterinary Pharmaceuticals · Indianapolis, IN

Our rating: Neutral

Neutral reaffirmed at $26.84, moderate conviction, November 9, 2026.

Breaks if: The Neutral view tips Cautious if free cash flow falls below $200M on a trailing twelve-month basis across two consecutive quarterly reports, or if revenue growth decelerates to below 2% year-over-year — either would signal the recovery narrative is stalling in a way the current valuation does not reflect. It tips Positive if free cash flow reaches $400M or above on a trailing twelve-month basis while revenue growth holds above 7% for two consecutive quarters, indicating that amortization drag is being offset by genuine operating leverage and the FCF yield is re-rating toward something that supports the current price.

Key figures

Market value$12.9B
Revenue, last 12 months$5.1B
Net income, last 12 months−$147M
Free cash flow, last 12 months$408M
Price to earningsn/a
Free cash flow yield3.2%
Dividend yield0.0%
Operating marginn/a
Return on equity−2.2%
Beta to the S&P 5001.22
Volatility, annualized47.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$1.3B11.3%$0.04$156M
June 30, 2026$1.4B10.2%$0.11$244M
March 31, 2026$1.4B14.9%$0.11−$38M
December 31, 2025$1.1B12.2%$-0.56$46M
September 30, 2025$1.1B10.4%$-0.07$127M
June 30, 2025$1.2B4.8%$0.02$180M
March 31, 2025$1.2B−1.0%$0.13−$69M
December 31, 2024$1.0B−1.4%$-0.02$130M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 51 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.